VANCOUVER, BC / ACCESS Newswire / December 10, 2025 / Lir Life Sciences Corp. (CSE:SKNY)(Frankfurt:N790, WKN: A41QA9) ("Lir" or the "Company") is pleased to announce the design of a new comparative cell-penetrating peptide-based uptake study (the "Study") of GLP/GIP[1]-based obesity therapies, further advancing its novel transdermal platform for obesity and metabolic disease. This initiative is intended to further the Company's research and development of patient-friendly, needle-free delivery options for incretin therapies. The Company believes that transdermal systems have the potential to improve comfort, accessibility, and long-term treatment adherence for individuals managing chronic metabolic conditions and evidence-based weight-loss treatments.
GLP, specifically GLP-1, and GIP act through complementary biological pathways that together can potentially improve glucose metabolism, energy balance, and weight regulation. By targeting both metabolic and appetite-related mechanisms, these hormones have the potential to address key drivers of obesity.[2]
In collaboration with its scientific partners, Lir Life Sciences has designed a controlled animal Study to evaluate the novel transdermal uptake of GLP/GIP-based obesity therapies using novel cell-penetrating peptide (CPP) formulations. In the investigation, Study subjects will be pre-treated with transdermal formulations of each drug, followed by an oral glucose challenge. Delivery effectiveness will be assessed by measuring blood glucose levels following a glucose intake. The Study will also compare the efficiency of transdermal delivery with standard subcutaneous injections. In practical terms, this means the research team will assess how effectively each molecule permeates the skin and supports glucose control relative to traditional injectable administration.
This comparative work is designed to map the performance envelope of Lir's CPP-enhanced transdermal platform across multiple GLP/GIP-based therapies and to inform future research and development priorities, including which molecules are best suited for needle-free delivery and subsequent Investigational New Drug (IND)-enabling studies. The results are intended to help identify the drug candidates that may align most effectively with the platform's capabilities, guiding the next stages of formulation optimization and clinical planning.
These efforts form part of Lir's broader research and development roadmap as it endeavours to create safe, effective, and patient-friendly alternatives to injectable GLP/GIP-based therapies.
"By evaluating three of the most clinically validated incretin therapies within the same delivery framework, we are generating the comparative data needed to prioritize the strongest candidates for transdermal advancement. Our aim with this study is to obtain clear insight into how these molecules behave with our CPP-enabled system and to inform our IND strategy," said Edward Mills, CEO of Lir Life Sciences.
About Lir Life Sciences Corp.
Lir Life Sciences is focused on researching and developing scalable and affordable treatments for obesity using novel drug delivery methods. The company is advancing a transdermal patch and other novel delivery systems that mimic GLP-1, a naturally occurring hormone that helps regulate appetite and blood sugar. These therapies could potentially offer an alternative to injectable drugs. The goal is to improve access, adherence, and cost-efficiency in both developed and emerging markets. LIR Life Sciences aims to address the global burden of obesity with practical solutions based on established compounds and proven science.
ON BEHALF OF LIR LIFE SCIENCES CORP.,
"Dr.Edward Mills,"
Chief Executive Officer
For more information, please contact:
Dr. Edward Mills
Chief Executive Officer
Tel: +1 888 436 7772
Email: investors@lirlife.com
Neither the CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
Cautionary Note Regarding Forward-Looking Information
This news release contains statements and information that, to the extent that they are not historical fact, may constitute "forward-looking information" within the meaning of applicable securities legislation based on current expectations, estimates, forecasts, projections, beliefs and assumptions made by management of the Company. Forward-looking information is generally identified by words such as "believe", "project", "aim", "expect", "anticipate", "estimate", "intend", "strategy", "future", "opportunity", "plan", "may", "should", "will", "would", and similar expressions and, in this news release, includes statements relating to the research and development activities of the Company, the financial and business prospects of the Company, its assets and other matters. Although the Company believes that the expectations and assumptions on which such forward- looking information are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that it will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking information in this news release. The forward-looking information included in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release is made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, unless so required by applicable laws.
[1] GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) are both gut hormones called incretins, which are released after eating. They both work by stimulating the pancreas to release more insulin, which helps lower blood sugar levels.
[2] https://diabetesjournals.org/diabetes/article/70/9/1956/137765/The-Role-of-GIP-in-the-Regulation-of-GLP-1-Satiety
SOURCE: Lir Life Sciences Corp.
View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/biotechnology/lir-life-sciences-completes-design-of-a-comparative-animal-study-investigating-cell-p-1116356
